BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/21/2025 8:16:42 AM | Browse: 2 | Download: 7
 |
Received |
|
2025-05-19 01:58 |
|
Peer-Review Started |
|
2025-05-19 01:58 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-06-05 09:38 |
|
Revised |
|
2025-06-14 09:36 |
|
Second Decision |
|
2025-08-04 02:52 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-08-04 11:41 |
|
Articles in Press |
|
2025-08-04 11:41 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-08-18 00:17 |
|
Publish the Manuscript Online |
|
2025-08-21 08:16 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Minireviews |
| Article Title |
Lepodisiran: From genetic targeting to cardiovascular promise: A detailed narrative review of the literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Affan Faisal, Abdul Basit, Abdullah Iftikhar, Muneeb Saifullah, M Khalil ur Rehmaan and Abdul M Basil |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Abdul M Basil, MD, Department of Medicine, Spinghar Medical University, 4th Alley, Char Rahe Qambar Kabul, Kabul 1001, Afghanistan. abdulmaboodbasil@outlook.com |
| Key Words |
Lepodisiran; Gene targeting; Atherosclerotic cardiovascular disease; Lipid lowering agents; Cardiovascular medicine |
| Core Tip |
Lepodisiran is a novel N-acetylgalactosamine-conjugated small interfering RNA that durably reduces lipoprotein(a) [Lp(a)] levels by silencing hepatic LPA message RNA expression. It offers up to 94% sustained Lp(a) reduction with minimal side effects and extended dosing intervals (6-12 months). This therapeutic breakthrough addresses a key residual cardiovascular risk factor previously untreatable with conventional lipid-lowering agents. |
| Publish Date |
2025-08-21 08:16 |
| Citation |
<p>Faisal A, Basit A, Iftikhar A, Saifullah M, Rehmaan MKU, Basil AM. Lepodisiran: From genetic targeting to cardiovascular promise: A detailed narrative review of the literature. <i>World J Cardiol</i> 2025; 17(8): 109657</p> |
| URL |
https://www.wjgnet.com/1949-8462/full/v17/i8/109657.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v17.i8.109657 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
